Robert W Cross Selected Research

Marburg Virus Disease

1/2022	A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
1/2021	Combination therapy protects macaques against advanced Marburg virus disease.
10/2015	Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert W Cross Research Topics

Disease

27	Infections 01/2022 - 09/2010
12	COVID-19 03/2022 - 01/2020
9	Vesicular Stomatitis 01/2022 - 12/2013
7	Ebola Hemorrhagic Fever 01/2022 - 10/2016
6	Lassa Fever (Fever, Lassa) 01/2020 - 01/2016
5	Virus Diseases (Viral Diseases) 01/2022 - 11/2018
3	Marburg Virus Disease 01/2022 - 10/2015
3	Fever (Fevers) 01/2021 - 10/2016
2	Crimean Hemorrhagic Fever 01/2021 - 01/2019
2	Henipavirus Infections 11/2020 - 12/2013
2	Convalescence 08/2020 - 01/2020
2	Interstitial Lung Diseases (Interstitial Lung Disease) 08/2020 - 01/2020
2	Viremia 01/2020 - 10/2015
1	Dermatitis 01/2022
1	Arthritis (Polyarthritis) 01/2022
1	Arthralgia (Joint Pain) 01/2022
1	Vascular Skin Diseases 01/2022
1	American Hemorrhagic Fever (Bolivian Hemorrhagic Fever) 01/2021
1	Disease Progression 01/2021
1	Cytokine Release Syndrome 01/2020
1	Inflammation (Inflammations) 01/2020
1	Viral Hemorrhagic Fevers (Viral Hemorrhagic Fever) 01/2019
1	Lymphopenia (Lymphocytopenia) 01/2017
1	Disseminated Intravascular Coagulation 10/2015
1	Epidemic Louse-Borne Typhus (Typhus) 02/2015
1	Nervous System Diseases (Neurological Disorders) 12/2013
1	Bacterial Infections (Bacterial Infection) 05/2011
1	Human Influenza (Influenza) 05/2011

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2022 - 05/2011
13	Monoclonal AntibodiesIBA 03/2022 - 01/2016
12	Glycoproteins (Glycoprotein)IBA 01/2022 - 12/2013
8	AntibodiesIBA 01/2022 - 01/2016
8	AntigensIBA 12/2021 - 12/2013
5	CytokinesIBA 01/2020 - 05/2011
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 05/2011
3	Neutralizing AntibodiesIBA 12/2021 - 10/2020
3	Antiviral Agents (Antivirals)IBA 11/2020 - 01/2019
2	EpitopesIBA 03/2022 - 11/2020
2	remdesivirIBA 01/2022 - 01/2021
2	bamlanivimabIBA 12/2021 - 10/2020
2	Protein CIBA 11/2020 - 10/2015
2	CollagenIBA 08/2020 - 01/2020
2	Immunoglobulin M (IgM)IBA 01/2020 - 02/2015
2	Immunoglobulin G (IgG)IBA 01/2020 - 02/2015
2	Indicators and Reagents (Reagents)IBA 11/2018 - 05/2011
2	ChemokinesIBA 01/2017 - 05/2011
2	EnzymesIBA 10/2015 - 02/2015
1	Plasminogen Activator Inhibitor 1IBA 01/2021
1	Combined VaccinesIBA 01/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2021
1	Subunit VaccinesIBA 01/2021
1	SolutionsIBA 01/2021
1	Hormones (Hormone)IBA 01/2020
1	HLA-DR Antigens (HLA-DR)IBA 01/2020
1	Recombinant ProteinsIBA 01/2020
1	ZincIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	NucleoproteinsIBA 01/2020
1	Polysaccharides (Glycans)IBA 11/2018
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 11/2018
1	Small Interfering RNA (siRNA)IBA 12/2017
1	InterferonsIBA 01/2017
1	Fibrinogen (Factor I)FDA Link 10/2015
1	FibrinIBA 10/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 10/2015
1	Antifibrinolytic Agents (Antifibrinolytics)IBA 10/2015
1	ImmunosorbentsIBA 02/2015
1	Ribavirin (Virazole)FDA LinkGeneric 03/2014
1	attachment protein GIBA 12/2013
1	GTP-Binding Proteins (G-Protein)IBA 12/2013
1	Blood Group Antigens (Blood Groups)IBA 09/2010

Therapy/Procedure

10	Therapeutics 01/2022 - 05/2011